SCHEMBL9732243

SCHEMBL9732243

Cc1ccccc1S(=O)(=O)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.41
HSD11B1 P28845 2/20 0.40
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
HTT P42858 2/20 0.39
RAPGEF4 Q8WZA2 1/20 0.39
LMNA P02545 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.38
ACHE P22303 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
EDNRA P25101 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097627 0.80 LMNA (0.42) HSD11B1SLC1A3SLC1A2SLC1A1RAPGEF4
SCHEMBL7504532 0.80 LMNA (0.42) HSD11B1SLC1A3SLC1A2SLC1A1RAPGEF4
SCHEMBL28051399 0.79 SLC1A3 (0.44) KAT6AHSD11B1SLC1A3SLC1A2SLC1A1
SCHEMBL27297268 0.79 SLC1A3 (0.51) KAT6AHSD11B1SLC1A3SLC1A2SLC1A1
SCHEMBL8742943 0.78 LMNA (0.41) HSD11B1SLC1A3SLC1A2SLC1A1RAPGEF4
SCHEMBL562674 0.78 SLC1A3 (0.39) HSD11B1SLC1A3SLC1A2SLC1A1HTT
SCHEMBL31575071 0.78 SLC1A3 (0.39) HSD11B1SLC1A3SLC1A2SLC1A1HTT
SCHEMBL6282158 0.77 SLC1A3 (0.41) KAT6AHSD11B1SLC1A3SLC1A2SLC1A1
SCHEMBL7999434 0.77 SLC1A3 (0.38) HSD11B1SLC1A3SLC1A2SLC1A1HTT
SCHEMBL1955701 0.76 KAT6A (0.43) KAT6AHSD11B1ALDH1A1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907341-A Pyridopyrimidinone derivatives, and preparation method and application thereof 武汉人福创新药物研发中心有限公司 2022-08-16 CN disclosed
WO-2022166974-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-08-11 WO disclosed
EP-2206707-B1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-07-23 EP disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
US-5175302-A Nucleophilic fluoroalkylation of aldehydes ETHYL CORPORATION (US) 1992-12-29 US disclosed
US-4999429-A Process for the preparation of α,α,β-1-trifluoro-1-olefinic derivatives ETHYL CORPORATION (US) 1991-03-12 US disclosed
US-4837327-A Process for nucleophilic fluoroalkylation of aldehydes ETHYL CORPORATION (US) 1989-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 KAT6A 3520/4885HSD11B1 3234/4885SLC1A3 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.